B. Johnson

发表

High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.

J. Minna, A. Gazdar, D. Carbone, 1992, Oncogene.

A cell cycle regulator potentially involved in genesis of many tumor types.

M. Skolnick, S. Tavtigian, K. Harshman, 1994, Science.

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.

B. Freidlin, D. Gandara, F. Shepherd, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer.

A. Gazdar, B. Johnson, J. Brennan, 1992, Journal of the National Cancer Institute. Monographs.

Biology of small cell lung cancer.

M. Kelley, B. Johnson, 1995, Lung cancer.

Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer.

B. Johnson, 1995, Chest.

myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens.

R. Makuch, A. Gazdar, E. Russell, 1991, Cancer research.

Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.

S. Larson, J. Mulshine, I. Avis, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors.

J. Minna, S. Naylor, A. Gazdar, 1988, The Journal of clinical investigation.

CDKN2 in HPV‐positive and HPV‐negative cervical‐carcinoma cell lines

F. Kaye, M. Kelley, G. Otterson, 1995, International journal of cancer.

Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival.

J. Minna, A. Gazdar, D. Carbone, 1993, Journal of the National Cancer Institute.

Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance.

B. Kramer, J. Minna, A. Gazdar, 1994, Lung cancer.

Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.

R. Makuch, J. Minna, J. Minna, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemosensitivity testing of human lung cancer cell lines using the MTT assay.

J. Minna, A. Gazdar, W. Degraff, 1988, British Journal of Cancer.

RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma.

S. Steinberg, J. Mulshine, R. Kratzke, 1994, Oncogene.

Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre.

D. Ettinger, E. Shaw, M. Tucker, 1997, Journal of the National Cancer Institute.

Lights flicker on fluorescence bronchoscopy in patients at risk for lung cancer.

B. Johnson, K. O'Neil, 1998, Journal of the National Cancer Institute.

Atrial Natriuretic Factor and Arginine Vasopressin Production in T\imor Cell Lines from Patients with Lung Cancer and Their Relationship to Serum Sodium1

S. Steinberg, B. Johnson, D. Ihde, 2006 .

Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma.

T. Lynch, P. Janne, N. Lindeman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Smoking, gender, and survival association with allele loss for the LOH11B lung cancer region on chromosome 11.

G. Bepler, B. Johnson, K. O'briant, 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene.

J. Battey, R. Makuch, J. Minna, 1986, The Journal of clinical investigation.

A prospective study of patients with lung cancer and hyponatremia of malignancy.

D. Venzon, B. Johnson, J. Chute, 1997, American journal of respiratory and critical care medicine.

Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.

S. Steinberg, A. Gazdar, A. Gazdar, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer.

R. Makuch, J. Minna, P. Bunn, 1986, The American journal of medicine.

Obstructive atelectasis in patients with small cell lung cancer. Incidence and response to treatment.

D. Venzon, B. Johnson, M. Edison, 1997, Chest.

Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.

R. Makuch, J. Minna, J. Whang‐Peng, 1985, Annals of internal medicine.

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

E. Lander, T. Golub, M. Meyerson, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Overview of genetic and molecular events in the pathogenesis of lung cancer.

M. Kelley, B. Johnson, 1993, Chest.

Best papers on lung cancer.

B. Johnson, 1992, Cancer investigation.

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE.

M. Kris, R. Herbst, V. Miller, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.

M. Kelley, B. Johnson, K. Nakagawa, 1995, Oncogene.

The biology of lung cancer.

B. Johnson, G. Richardson, 1993, Seminars in oncology.

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

M. Meyerson, Joon-Oh Park, P. Jänne, 2008, British Journal of Cancer.

The development of small cell lung cancer in the contralateral lung of a patient surviving 8 years after the original diagnosis of small cell lung cancer

B. Johnson, K. Devaney, Thomas J. Walsh, 1988, Cancer.

Obesity and therapy-related toxicity in patients treated for small-cell lung cancer.

S. Steinberg, B. Johnson, D. Ihde, 1995, Journal of the National Cancer Institute.

Second lung cancers in patients successfully treated for lung cancer.

B. Johnson, J. Chute, P. Cortazar, 1997, Seminars in oncology.

Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop.

J. Mulshine, B. Johnson, J. Battey, 1995, Lung cancer.

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.

W. Wilson, S. Steinberg, C. Takimoto, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

J. Soria, V. Papadimitrakopoulou, B. Johnson, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI).

P. Janne, N. Lindeman, D. Kwiatkowski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer

S. Steinberg, A. Gazdar, E. Russell, 1996, Journal of cellular biochemistry. Supplement.

Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer.

M. Kelley, B. Johnson, 1998, Oncology.

Small cell lung cancer.

A. Gregor, P. Rocmans, P. Postmus, 1997, Lung cancer.

Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines.

M. Kelley, J. Trepel, B. Johnson, 1998, Lung cancer.

Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors.

R. Jensen, B. Johnson, Y. Ohsaki, 1993, Cancer research.

Association of chromosome 11 locus D11S12 with histology, stage, and metastases in lung cancer.

G. Bepler, M. Garcia-Blanco, P. Zimmerman, 1998, Cancer detection and prevention.

Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma.

J. Temel, T. Lynch, P. Janne, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study.

R. Herbst, P. Fidias, J. Heymach, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results.

R. Herbst, J. Heymach, D. Prager, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

S. Kopetz, D. Hong, M. Overman, 2019 .

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

M. Kris, V. Rusch, I. Wistuba, 2021 .

NY-ESO-1 may be a potential target for lung cancer immunotherapy.

D. Schrump, B. Johnson, A. Mixon, 1999, The cancer journal from Scientific American.

TOBACCO AND LUNG CANCER

B. Johnson, H.Daintree Johnson, 1963 .

Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides.

M. Kelley, B. Johnson, K. Becker, 1994, Cancer letters.

Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer.

B. Johnson, P. Cortazar, B. Johnson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer.

E. Shaw, M. Tucker, M. Kelley, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines.

J. Battey, A. Gazdar, M. Birrer, 1990, Journal of the National Cancer Institute.

Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations.

A. Gazdar, E. Russell, B. Johnson, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antitumor activity of magainin analogues against human lung cancer cell lines.

A. Gazdar, B. Johnson, Y. Ohsaki, 1992, Cancer research.

myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course.

R. Makuch, J. Minna, A. Gazdar, 1987, The Journal of clinical investigation.

A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.

R. Simon, B. Johnson, J. Chute, 2000, Journal of the National Cancer Institute.

Concurrent approaches to combined chemotherapy and chest radiotherapy for the treatment of patients with limited stage small cell lung cancer.

B. Johnson, 1994, Lung cancer.

Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer.

J. Battey, J. Minna, A. Gazdar, 1984, Current topics in microbiology and immunology.

Is more better? Chemotherapy for patients with extensive-stage small-cell lung cancer.

B. Johnson, 2001, Journal of the National Cancer Institute.

Transcriptional subtype-specific microenvironmental crosstalk and tumor cell plasticity in metastatic pancreatic cancer

James M. McFarland, Hannah L Williams, W. Hahn, 2020, bioRxiv.

NCI‐navy medical oncology branch cell line data base

J. Minna, A. Gazdar, D. Carbone, 1996, Journal of cellular biochemistry. Supplement.

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.

F. Khuri, H. Safran, B. Johnson, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics of cell lines established from human gastric carcinoma.

R. Jensen, J. G. Park, J. Trepel, 1990, Cancer research.

CHARACTERISTICS OF COLORECTAL CARCINOMA CELL LINES paraffin embedded sections of xenografts

A. Gazdar, J. G. Park, B. Johnson, 2006 .

Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years.

S. Steinberg, J. Mulshine, B. Johnson, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer.

S. Naylor, A. Gazdar, W. Lee, 1990, Cancer research.

Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer

J. Minna, S. Naylor, B. Johnson, 1987, Nature.

Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes.

M. Wei, M. Lerman, E. Stanbridge, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Cloning and characterization of TCTA, a gene located at the site of a t(1;3) translocation.

B. Johnson, I. Kirsch, P. Aplan, 1995, Cancer Research.

Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer.

J. Battey, J. Minna, A. Gazdar, 1986, Cold Spring Harbor symposia on quantitative biology.

Mutational inactivation of aminoacylase‐1 in a small cell lung cancer cell line

W. Franklin, B. Johnson, M. Moore, 1998, Genes, chromosomes & cancer.

The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.

F. Kaye, J. Testa, M. Kelley, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A G-to-A single nucleotide polymorphism in the human alpha 2 delta 2 calcium channel subunit gene that maps at chromosome 3p21.3.

M. Wei, F. Duh, M. Lerman, 2000, Molecular and Cellular Probes.

Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines.

J. Minna, D. Carbone, Y. Sekido, 1994, Cancer research.

myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines.

R. Makuch, A. Gazdar, B. Johnson, 1988, Cancer research.

Characterization of two cell lines with distinct phenotypes established from a patient with small cell lung cancer.

G. Bepler, A. Gazdar, B. Johnson, 1987, Cancer research.

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

Nicholas D. Camarda, S. Carter, A. Iafrate, 2020, Nature Genetics.

Molecular genetic characterization of neuroendocrine lung cancer cell lines.

F. Kaye, H. Brauch, B. Zbar, 1995, Anticancer research.

Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies.

S. Naylor, A. Gazdar, H. Brauch, 1989, Journal of the National Cancer Institute.

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

J P Pignon, R. Arriagada, J. Pignon, 1999, The New England journal of medicine.

Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer.

R. Makuch, B. Johnson, M. Krehbiel, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MDR1 gene expression in lung cancer.

I. Pastan, M. Gottesman, A. Gazdar, 1989, Journal of the National Cancer Institute.

Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors.

W. Hayes, B. Johnson, E. Glatstein, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer.

J. Minna, D. Carbone, S. Meltzer, 1992, Cancer research.

Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.

S. Steinberg, A. Gazdar, E. Russell, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.

S. Steinberg, J. Mulshine, M. Kelley, 1995, Journal of the National Cancer Institute.

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, A. Iafrate, C. Rudin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines.

M. Lan, E. Russell, B. Johnson, 1993, Cancer research.

Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.

J. Minna, A. Gazdar, D. Carbone, 1992, Cancer research.

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, A. Iafrate, C. Rudin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p.

J. Catino, B. Johnson, D. Carney, 1987, Cancer research.

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.

R. Simon, B. Johnson, J. Chute, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of small-cell lung cancer.

B. Johnson, B. Johnson, 2002, Clinics in chest medicine.

Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: Comparison of non‐small cell lung cancer and small cell lung cancer

S. Steinberg, J. Minna, A. Gazdar, 1996, Journal of cellular biochemistry. Supplement.

Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.

S. Steinberg, J. Minna, A. Gazdar, 1993, Cancer research.

Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial.

S. Steinberg, J. Minna, A. Gazdar, 1990, Journal of the National Cancer Institute.

Female patients with small cell lung cancer live longer than male patients.

S. Steinberg, B. Johnson, D. Ihde, 1988, The American journal of medicine.

A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

P. Fidias, T. Lynch, G. Shapiro, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.

S. Steinberg, C. Takimoto, B. Johnson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.

R. Heist, S. Dimitrijević, D. Camidge, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

S. Kopetz, D. Hong, M. Overman, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer

R. Herbst, A. Ryan, B. Johnson, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

New targets and new treatments in non-small cell lung cancer

B. Johnson, 2004 .

Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.

M. Christian, M. Kelley, S. Piscitelli, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Second lung cancers in patients after treatment for an initial lung cancer.

B. Johnson, Bruce E. Johnson, 1998, Journal of the National Cancer Institute.

Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years.

P. Okunieff, D. Venzon, B. Johnson, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung

B. Johnson, O. Breathnach, B E Johnson, 1999, Cancer.

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.

P. Jänne, H. Hatabu, D. Jackman, 2014, Clinical radiology.

Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs.

D. Venzon, B. Johnson, D. Ihde, 1993, Archives of internal medicine.

Ectopic production and processing of atrial natriuretic peptide in a small cell lung carcinoma cell line and tumor from a patient with hyponatremia

B. Johnson, Hao‐Chia Chen, R. Harris, 1997, Cancer.

NCCN: Small cell lung cancer.

B. Johnson, 2001, Cancer control : journal of the Moffitt Cancer Center.

Calcitonin elevation in small cell lung cancer without ectopic production.

D. Venzon, M. Kelley, B. Johnson, 1994, American journal of respiratory and critical care medicine.

Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer.

J. Mulshine, M. Kelley, I. Avis, 1997, Chest.

An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC).

M. Socinski, R. Govindan, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute.

P. Okunieff, D. Venzon, B. Johnson, 1997, Mayo Clinic proceedings.

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

M. Kris, V. Rusch, I. Wistuba, 2021 .

Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease.

D. Sugarbaker, D. Finkelstein, D. Kwiatkowski, 2001, The Journal of thoracic and cardiovascular surgery.

Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer.

D. Venzon, M. Kelley, B. Johnson, 1996, Chest.

Combined modality therapy in small cell lung cancer.

J. Jett, R. Arriagada, A. Gregor, 1994, Lung cancer.

P03.04 Phase II Study of TKIs as Neo(adjuvant) Therapy in Stage II–III Resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 Alterations

I. Wistuba, Wei Yu, D. Kwiatkowski, 2021 .

C306A single nucleotide polymorphism in the human CEBPD gene that maps at 8p11.1-p11.2.

M. Lerman, B. Johnson, E. Sterneck, 2001, Molecular and Cellular Probes.

Lung carcinoma metastasis at the site of central venous access.

B. Johnson, O. Breathnach, D. Cruser, 1998, Chest.

Lung cancer presenting with solitary bone metastases. Case 2: acrometastasis as an initial presentation of non-small-cell lung carcinoma.

P. Jänne, M. Datta, B. Johnson, 1999, Journal of Clinical Oncology.

Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.

J. Minna, A. Gazdar, W. Degraff, 1991, British Journal of Cancer.

Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium.

S. Steinberg, J. Mulshine, B. Johnson, 1993, Cancer research.

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer

S. Steinberg, A. Gazdar, E. Russell, 1996, Journal of cellular biochemistry. Supplement.

Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin

J. Minna, A. Gazdar, H. Pass, 1993 .

Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial.

S. Steinberg, J. Minna, A. Gazdar, 1990, Journal of the National Cancer Institute.

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.

J. Berzofsky, J. Minna, D. Carbone, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancer.

J. Battey, E. Sausville, J. Minna, 1986, Princess Takamatsu symposia.

Recessive oncogenes and chromosomal deletions in human lung cancer

J. Minna, A. Gazdar, F. Kaye, 1989 .

Genetic mechanisms of solid tumor oncogenesis.

M. Kelley, B. Johnson, 1994, Advances in internal medicine.

A G-toA single nucleotide polymorphism in the human Alpha 2 Delta 2 calcium channel subunit gene that maps at chromosome 3 p 21 . 3

M. Wei, F. Duh, M. Lerman, 2022 .